Table 3. Modeled projected effectiveness of two RV vaccines against RVGE-related hospitalizations in Malaysia.
| Serotypes | Proportion of total serotypes in Malaysia (%) | Serotype-specific of pentavalent RV vaccine (RV5) A | Attributable effectiveness: Base case scenario for RV5 (%)B | Attributable effectiveness: sensitivity analysis for RV5 (%)C | Serotype-specific of monovalent RV vaccine (RV1) D | Attributable effectiveness: Base case scenario for RV1 (%)B | Attributable effectiveness: sensitivity analysis for RV1 (%)C |
|---|---|---|---|---|---|---|---|
| G1 |
34.7 |
0.95 |
33.0 |
33.0 |
1.0 |
34.7 |
34.7 |
| G2 |
2.5 |
0.88 |
2.2 |
2.2 |
1.0 |
2.5 |
2.5 |
| G3 |
1.1 |
0.93 |
1.0 |
1.0 |
0.95 |
1.0 |
1.0 |
| G4 |
34.6 |
0.89 |
30.8 |
30.8 |
0.94E |
32.5 |
32.5 |
| G9 |
12.7 |
1.0 |
12.7 |
12.7 |
0.92 |
11.7 |
11.7 |
| Mixed / untypeable |
14.4 |
- |
13.0 |
0 |
- |
13.0 |
0 |
|
Overall weighted effectiveness |
|
|
92.7 |
79.7 |
|
95.4 |
82.8 |
| Overall vaccine effectiveness based on 95% coverage | 88.1 | 75.7 | 90.6 | 78.7 |
Note: RV, rotavirus. (A) Pentavalent human-bovine reassortant RV vaccine (Rotateq®, Merck Co.; ref. 3) (B) Base case scenario assumes 90% efficacy against mixed and untypeable serotypes. (C) Sensitivity analysis assumes 0% efficacy against mixed and untypeable serotypes. (D) Monovalent attenuated human RV vaccine (Rotarix®, GlaxoSmithKline Biologicals; ref. 5). The efficacy data for RV1 are for prevention of severe RV gastroenteritis based on a score of 11 using the 20-point Vesikari scale. (E) No efficacy figure for G4 was available, so efficacy for non-G1 was taken